NCT03177057

Brief Summary

This pilot clinical trial studies how well Self Monitoring And Readiness Texting (SMART) project works in sun exposure and protection behaviors. Measuring how behavior tracking and individually tailored messages affect risk behaviors in patients with skin cancer may help doctors plan the best prevention plan and decrease national melanoma incidence and mortality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
114

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2013

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 23, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2014

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2014

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

June 2, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 6, 2017

Completed
Last Updated

August 1, 2018

Status Verified

July 1, 2018

Enrollment Period

1.3 years

First QC Date

June 2, 2017

Last Update Submit

July 31, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in ultraviolet radiation (UV) exposure and sun protection behaviors based on behavior tracking and individually tailored daily text messages

    Multiple variable regression models will be performed to examine the effect of the intervention on the outcomes. All post-baseline outcomes will be used as dependent variables. The baseline scores, intervention group, and time of the assessment will be included. To account for the within subject correlation of the responses, we will fit the model using Generalized Estimating Equations assuming an autoregressive working correlation matrix for each subject. Any p-value from the pairwise comparison that is less than 0.05 will be considered worthy of further study.

    Baseline to up to 2 weeks

Secondary Outcomes (1)

  • Mediators and moderators of the intervention on behavior

    At 2 weeks

Study Arms (4)

Arm I (self-monitoring)

EXPERIMENTAL

ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.

Behavioral: Compliance MonitoringOther: Questionnaire Administration

Arm II (text messages)

EXPERIMENTAL

ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.

Other: Health TelemonitoringOther: Questionnaire Administration

Arm III (self-monitoring, text messages)

EXPERIMENTAL

ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.

Behavioral: Compliance MonitoringOther: Health TelemonitoringOther: Questionnaire Administration

Arm IV (questionnaire administration)

SHAM COMPARATOR

ARM IV (CONTROL GROUP): Patients complete study assessments.

Other: Questionnaire Administration

Interventions

Record behavior

Arm I (self-monitoring)Arm III (self-monitoring, text messages)

Receive health monitoring text messages

Arm II (text messages)Arm III (self-monitoring, text messages)

Ancillary studies

Arm I (self-monitoring)Arm II (text messages)Arm III (self-monitoring, text messages)Arm IV (questionnaire administration)

Eligibility Criteria

Age18 Years - 29 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women from the Philadelphia metropolitan area who own a mobile phone and who meet criteria for at least moderate risk of skin cancer based on a brief risk assessment tool

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

Location

Study Officials

  • Carolyn Heckman

    Fox Chase Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 2, 2017

First Posted

June 6, 2017

Study Start

April 23, 2013

Primary Completion

July 30, 2014

Study Completion

December 31, 2014

Last Updated

August 1, 2018

Record last verified: 2018-07

Locations